Skip to main content
v2026.11,610 entries · CC-BY 4.0
LAC HealthLaboratory & ResearchLab & research supplies.Reagents, consumables, PPE & instruments — documented, fast, chain-of-custody shipping.Shop lac.us lac.us

Direct comparison

Exclusive vs Non-Exclusive IP License

Exclusive licenses grant sole rights, often needed to justify startup investment. Non-exclusive licenses allow multiple licensees. Compare when to use each.

Side-by-side comparison

DimensionExclusive LicenseNon-Exclusive License
Number of licenseesOne licensee holds the rights; university typically cannot license or practice the technology commercially itselfMultiple licensees can hold rights to the same technology simultaneously
Best fitInventions needing substantial, capital-intensive further development (drugs, devices, platform hardware)Broadly applicable research tools, reagents, datasets, software components, algorithms
Startup/VC investment caseUsually necessary — investors want protection from a competitor licensing the same IPRarely required — no multi-year development gap to protect
Typical negotiating leverage for the TTOHigher — can extract equity, higher royalties, milestone payments in exchange for exclusivityLower per deal — value comes from volume of licensees, not per-deal leverage
Diligence / milestone obligationsStandard practice — reversion or termination rights if licensee misses development milestonesRarely needed — no single licensee’s performance is load-bearing
35 U.S.C. §204 US manufacturing preferenceApplies — exclusive US licensee generally must agree to substantially manufacture in the US (waivable)Does not apply
35 U.S.C. §203 march-in exposureSame statutory exposure as any license — practical-application failure risk is more concentrated with one licenseeSame statutory exposure, but risk is diluted across multiple licensees
Administrative burdenLower per-technology relationship count, but higher-stakes monitoring of one licensee’s diligenceHigher relationship count (multiple simultaneous licensees) but lighter monitoring per licensee
Revenue modelLarger potential per-deal royalty/equity, concentrated in one outcomeSmaller per-deal royalty, aggregated across many licensees
Risk if licensee underperformsHigh — technology can sit undeveloped and unavailable to anyone else absent reversion rightsLow — other licensees, or new ones, remain available regardless
Common hybrid variantField-of-use or territory-limited exclusivity; time/diligence-conditioned exclusivityN/A — non-exclusivity is already the more flexible default

Common questions

FAQ

Can a license be exclusive in one respect and non-exclusive in another?+

Yes. Field-of-use and territory carve-outs are common — a licensee can be exclusive for one application or region while the university remains free to license the same patent non-exclusively, or exclusively to a different party, elsewhere.

Does an exclusive license always produce more revenue than a non-exclusive one?+

Not automatically. An exclusive deal can produce a larger single payout (equity, milestones, higher royalty rate), but a non-exclusive strategy that licenses the same technology to many companies can out-earn it in aggregate, especially for broadly applicable tools where adoption volume drives revenue.

What is a "sole" license, and is it the same as exclusive?+

No. A sole license excludes other third-party licensees but still allows the university itself to practice the technology, unlike a true exclusive license, where the university typically agrees not to practice it commercially either. Sole licenses are uncommon and are a narrow middle case between exclusive and non-exclusive.

Do federal funding rules treat exclusive licenses differently from non-exclusive ones?+

Yes, for federally funded inventions. Under 35 U.S.C. §204, an exclusive licensee to sell or use the invention in the US generally must agree to substantially manufacture products in the US, subject to a waiver process — a requirement that does not attach to non-exclusive licenses. March-in rights under 35 U.S.C. §203 apply regardless of exclusivity, but the practical risk is more concentrated when a single exclusive licensee fails to commercialize.

Can a non-exclusive license later be converted to exclusive?+

It can be, if the agreement or a later amendment allows it and no conflicting non-exclusive licenses to the same rights are already in place — but converting an existing non-exclusive licensee to exclusive status typically requires either that no other licensees hold overlapping rights, or negotiating those other licenses out first.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →